Tarceva set for first line treatment

Published: 2011-12-26 06:57:00

Updated: 2011-12-26 06:57:00

Roche’s oral lung cancer treatment Tarceva (erlotinib) has been approved by the Korea Food and Drug Administration as a first line treatment for people with newly diagnosed advanced non-small cell lung cancer (NSCLC) with EGFR (epidermal growth factor receptor) activating mutations lived without ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK